Elliott Statement on ARYZTA
23.11.2020 08:00:00 EET | Business Wire | Press release
Elliott Advisors (UK) Limited (“Elliott” or “we”) notes the press speculation regarding a potential offer for ARYZTA AG (the “Company”) and issues the following clarification.
Elliott confirms that on Wednesday November 18th 2020 it made a proposal to the Board of Directors of the Company to potentially acquire all of the outstanding shares of ARYZTA AG for an indicative price of CHF 0.80 per share. This followed several months of work conducted with the support of the Company and its Board of Directors, both before and after the Extraordinary General Meeting on September 16th 2020. We also note press speculation regarding the financing for such an acquisition and the refinancing of the Company. We confirm that the financing of the potential offer is available and that refinancing arrangements for the Company’s existing debt are at a very advanced stage. We require the Board of Directors’ recommendation of our potential offer and the Company’s support to finalise our refinancing arrangements.
The public tender offer would be subject to customary offer conditions to be specified by Elliott. The information contained in this statement is neither an offer to purchase shares in ARYZTA AG nor a solicitation of an offer to sell ARYZTA AG shares or any other securities of ARYZTA AG nor does it constitute a public tender offer with respect to any ARYZTA AG shares or any other ARYZTA AG securities.
About Elliott
Elliott Management Corporation manages approximately $41 billion of assets. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201122005093/en/
Contact information
London
Sarah Rajani CFA
Elliott Advisors (UK) Limited
T: +44 (0)20 3009 1475
srajani@elliottadvisors.co.uk
Switzerland
Martin Meier-Pfister
IRF
T: +41 43 244 81 40
M: +41 79 200 85 00
meier-pfister@irf-reputation.ch
Ireland
Jack Hickey
Powerscourt
T: +353 (0)1 536 0683
M: +353 (0)83 448 8339
jack.hickey@powerscourt-group.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo
Elliptic Announces Circle’s Participation in Agentic Design Partner Program9.7.2026 15:15:00 EEST | Press release
Elliptic, the global leader in digital asset intelligence, today announced that an affiliate of Circle Internet Group, Inc. (‘Circle’) (NYSE:CRCL) has joined its Agentic Design Partner Program, bringing together infrastructure providers, compliance teams, and technology leaders to help shape compliance solutions for autonomous, AI-driven financial activity. This momentum follows an investment from Circle Ventures, the corporate venture arm of Circle, and builds on a longstanding collaboration between the companies. Circle has been an Elliptic customer for multiple years and has expanded its use of Elliptic’s compliance capabilities across a range of digital asset initiatives. As stablecoins, tokenized assets, and AI-powered applications become increasingly integrated into financial services, new compliance challenges are emerging. Elliptic’s agentic compliance layer addresses these challenges by combining unique datasets, a scalable query platform and a set of agents that can detect an
Russell Investments Announces New Long-Term Owners9.7.2026 15:00:00 EEST | Press release
Russell Investments, the global investment solutions provider, today announced that an investor consortium (the “Investor Consortium”) led by B Capital, a global multi-stage investment firm, and including California Public Employees' Retirement System ("CalPERS"), has agreed to acquire the firm from TA Associates (“TA”) and Reverence Capital Partners (“RCP”). The transaction comes as Russell Investments marks over $416 billion in global assets under management (AUM) and has experienced more than 15% organic growth over the past two years. Russell Investments has been a trusted, independent partner to its clients for over 90 years. Its open-architecture model delivers portfolio solutions that source from the full landscape of the asset management industry across public and private markets. With a shared vision for the company’s next phase of growth, the new owners are bringing to Russell Investments long-term capital, advanced technology expertise, and experience scaling next-generation
Esri and Global Partners Release HydroSHEDS v2 for the Americas9.7.2026 15:00:00 EEST | Press release
Esri has made HydroSHEDS v2 publicly available for the first time. Confluvio Consulting led the development of the HydroSHEDS v2 foundational dataset in partnership with the German Aerospace Center (DLR) and Esri, whose geographic information system (GIS) technology will provide users with the data. A major innovation in global hydrographic capabilities, this hydrographic framework is the result of a collaboration initiated by World Wildlife Fund (WWF) and McGill University. HydroSHEDS v2 will support a broad range of applications, including flood risk assessments, freshwater ecosystem conservation, infrastructure planning, water resource management, environmental modeling, scientific research, and operational decision-making. The initial release of HydroSHEDS v2 provides comprehensive hydrographic coverage for North, Central, and South America, and marks the beginning of a phased global rollout. By making these datasets available through ArcGIS Living Atlas, Esri is enabling GIS profe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom